Precision medicine in action, with Cary Claiborne
Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.
Newsletters and Deep Dive digital magazine
Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.
The UK government has asked the NHS to start putting together the platforms to allow anonymised primary care patient data to be used by researchers.
The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.
The FDA said it needs more information before it can approve Regenxbio's gene therapy for Hunter syndrome, in a devastating decision for patients.
Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?
Editor's Picks
Newsletters and Deep Dive
digital magazine